On the other hand, a significant increase in respiratory complications, particularly pneumonitis, which was ranked as the second most commonly occurring complication, was seen in the anti-PD1 group (4% vs. 2%; p = 0.01); however, it is not clear whether this was driven by pembrolizumab, nivolumab, or both. The gene discussed is PDCD1; the disease is pneumonitis.